1Camera A, Annino L, Chiurazzi F, et al. GIMEMA ALL-Rescue 97 : a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia [ J ]. Haematologica, 2004,89 ( 2 ) : 145 -153
2Sung W J, Kim DH, Sohn SK, et al. Phase Ⅱ trial of amsacrine plus intermediate-dose Ara-C ( IDAC ) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia[ J]. Jpn J Clin Oncol,2005,35(10) :612 -616.
3Specchia G,Pastore D,Carluccio P, et al.FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia [J]. Ann Hematol,2005,84(12) :792 -795.
4Hiroatsu I, Hiroshi S, Kenjiro K, et al. Twenty years' experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group [ J ]. Int J Hematol, 2004,79( 1 ) :79 -84.
7Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper- CVAD and imatinib mesylate [ J ]. Blood, 2004,103 ( 12 ) :4396 - 4407.
8Kraus M, Ruckrich T, Reich M, et al. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells [ J ]. Leukemia,2007,21 ( 1 ) :84 -92.
10Jorge C, Deborah T, Charles K, et al. Phase Ⅰ study of bortezomib in refractory or relapsed acute leukemias [ J ]. Clin Cancer Res,2004,10(10) :3371 -3376.
4Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics,treatment results and prognosis with salvage therapy [J]. Cancer,1999, 86(7): 1216-30.
5Mengarelli A, Iori AP, Guglielmi C, et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia [J].Haematologica, 2002, 87(2): 52-8.
6Bearman SI, Applbaum FR, Buckner CD, et al. Regimen related toxicity in patients undergoing bone marrow transplantation [J]. J Clin Oncol, 1988, 6(11): 1562-7.
7Demirer T, Buckner CD, Appelbaum FR, et al. Busulfan, cyclophosphamide and franctionated total irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels[J ]. Bone Marrow Transplant, 1996, 17(5): 341-6.
8Singhal S, Powles R, Henslee-Downey PJ, et al. Allogeneic transplantation from HLA-matched sibling or partially HLAmismatched related donors for primary refractory acute leukemia[J]. Bone Marrow Transplant, 2002, 29(4): 291-5.
9Kolb HJ, Schmid C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras[J ]. Blood, 2004, 103(3): 767-76.
10Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia[J]. Blood, 1995, 86(9): 2041-50.
